A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia

Hydroxyurea is an antimetabolite drug that induces fetal haemoglobin in sickle cell disease. However, its clinical usefulness in β-thalassaemia is unproven. We conducted a randomised, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of hydroxyurea in transfusion-de...

Descripción completa

Detalles Bibliográficos
Autores principales: Yasara, Nirmani, Wickramarathne, Nethmi, Mettananda, Chamila, Silva, Ishari, Hameed, Nizri, Attanayaka, Kumari, Rodrigo, Rexan, Wickramasinghe, Nirmani, Perera, Lakshman, Manamperi, Aresha, Premawardhena, Anuja, Mettananda, Sachith
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8854735/
https://www.ncbi.nlm.nih.gov/pubmed/35177777
http://dx.doi.org/10.1038/s41598-022-06774-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8854735/
https://www.ncbi.nlm.nih.gov/pubmed/35177777
http://dx.doi.org/10.1038/s41598-022-06774-8

Ejemplares similares